Tavapadon

Tavapadon

Clinical data
Other names	CVL-751; PF-6649751; PF-06649751
Identifiers
IUPAC name 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione
CAS Number	1643489-24-0
PubChem CID	86764100
ChemSpider	48062699
UNII	PT4P8MJP8L
KEGG	D11431
ChEMBL	ChEMBL3697617
Chemical and physical data
Formula	C19H16F3N3O3
Molar mass	391.350 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
InChI InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27) Key:AKQXQLUNFKDZBN-UHFFFAOYSA-N

Tavapadon (developmental code names CVL-751, PF-6649751, PF-06649751) is a dopamine receptor agonist which is under development by Pfizer and Cerevel Therapeutics for the treatment of Parkinson's disease. It acts as a selective partial agonist of the dopamine D₁ (K_i = 8.54 nM) and D₅ receptors. It also shows biased agonism for G_s-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.

See also

• CVL-871